HOPKINTON, Mass., Aug. 7 /EMWNews/ -- Alseres

Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced that they will host a

conference call on Thursday, August 14th, 2008 at 9:00am EDT to review the

second quarter ending June 30, 2008 and discuss other matters related to

the Company.



    



    To access the conference call, please dial 877-879-6201 for domestic

and 719-325-4816 international. The code for this conference call is

4315502. Please dial in 5 to 10 minutes prior to the scheduled start time.

A replay of the call will be posted on the Investor Relations section of

our website, http://www.alseres.com, within 48 hours following the conference call

and will be available through Thursday, August 28th, 2008.

    About Alseres Pharmaceuticals, Inc.



    Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of

therapeutic and diagnostic products primarily for disorders in the central

nervous system (CNS). The Company maintains a world-class intellectual

property position in the field of regenerative therapeutics. The Company's

focus is reflected in several important initiatives. Cethrin, a

recombinant- protein-based drug designed to promote nerve repair after

acute spinal cord injury, demonstrated positive interim results in a Phase

I/IIa clinical trial. The Company's research and pre-clinical programs

include, Inosine for the treatment of spinal cord injury and stroke,

Oncomodulin for the treatment of ocular injury and disease and research

programs directed at a number of regenerative therapies including bone

repair. The Company has a robust molecular imaging development program

targeting diagnosis of Parkinson's disease and potentially dementia. The

Company's lead molecular imaging product candidate is Altropane which is in

Phase III clinical trials for the diagnosis of Parkinsonian Syndromes

including Parkinson's disease. The Company has research collaborations with

Harvard Medical School and Children's Hospital Boston.



    Forward-Looking Statements



    The foregoing release contains certain forward-looking statements

within the meaning of the Private Securities Litigation Reform Act of 1995.

Forward- looking statements include statements regarding Alseres' future

expectations, beliefs, intentions, goals, strategies, plans or prospects

regarding the future, including the development and commercialization of

Altropane and Cethrin, the prospects of the Company's CNS and regenerative

therapeutics programs, the Company's strategies to develop and

commercialize axon regeneration technologies and the breadth of the

Company's technologies and intellectual property portfolio. Forward-looking

statements can be identified by terminology such as "anticipate,"

"believe," "could," "could increase the likelihood," "estimate," "expect,"

"intend," "is planned," "may," "should," "will," "will enable," "would be

expected," "look forward," "may provide," "would" or similar terms,

variations of such terms or the negative of those terms. Such

forward-looking statements involve known and unknown risks, uncertainties

and other factors including those risks, uncertainties and factors referred

to in the Company's Quarterly Report on Form 10-Q for the quarter ended

March 31, 2008 filed with the Securities and Exchange Commission under the

section "Risk Factors," as well as other documents that may be filed by

Alseres from time to time with the Securities and Exchange Commission. As a

result of such risks, uncertainties and factors, the Company's actual

results may differ materially from any future results, performance or

achievements discussed in or implied by the forward-looking statements

contained herein. Alseres is providing the information in this press

release as of this date and assumes no obligations to update the

information in this press release.



    Alseres, Cethrin and Altropane are registered trademarks of Alseres

Pharmaceuticals, Inc.






    Contact:

    Sharon Correia - 508-497-2360 ext. 224

    Alseres Pharmaceuticals, Inc.

    [email protected]



    Adam Friedman - 212-981-2529 ext. 18

    Adam Friedman Associates

    [email protected]